Intensity Therapeutics, Inc. announced on June 30, 2025, that its lead investigational product candidate, INT230-6, achieved a 100% complete response rate in murine models of Malignant Peripheral Nerve Sheath Tumor (MPNST). This significant finding was observed at 21 days in a study conducted at the Staedtke-Bai laboratory at Johns Hopkins University. In contrast, all tumors in the control group continued to grow.
MPNST is a rare and aggressive type of sarcoma with limited effective therapies and a poor five-year survival rate of 20% to 50%. Dr. Renyuan Bai, coordinating scientist for the study, noted that no other small molecule drug has achieved such an effect in their lab for this difficult-to-treat neurological model.
This preclinical success marks the first time INT230-6 has been used for a neurological-specific tumor, demonstrating meaningful results similar to those seen in other in vivo models. The company plans to conduct further preclinical research in other neurological cancer models, potentially expanding the therapeutic scope of INT230-6.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.